MLTX vs NSC · $1.41B cap vs P/E 18, rev $6.46B
MoonLake Immunotherapeutics (MLTX) versus Norfolk Southern Corporation (NSC) — a side-by-side from cached financials, not a winner call.
MoonLake Immunotherapeutics (MLTX) is a biotechnology company listed on US.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
MLTX does not have a complete income-statement cache yet.
Latest reported NSC revenue for 2026-06-30 was $6.46B. Net income was $1.28B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
MLTX currently screens at market cap $1.41B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Not investment advice. Open the MLTX and NSC stock pages for the full models.
Not investment advice.